These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 28135602)
1. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Fréour T; Barrière P; Masson D Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602 [TBL] [Abstract][Full Text] [Related]
2. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram. Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758 [TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758 [TBL] [Abstract][Full Text] [Related]
4. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Anderson RA; Rosendahl M; Kelsey TW; Cameron DA Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732 [TBL] [Abstract][Full Text] [Related]
5. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324 [TBL] [Abstract][Full Text] [Related]
6. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. Anderson RA; Cameron DA J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458 [TBL] [Abstract][Full Text] [Related]
7. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor. Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118 [TBL] [Abstract][Full Text] [Related]
8. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone. Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112 [TBL] [Abstract][Full Text] [Related]
9. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720 [TBL] [Abstract][Full Text] [Related]
10. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer. Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099 [TBL] [Abstract][Full Text] [Related]
11. The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer. Anderson RA; Su HI Front Endocrinol (Lausanne); 2020; 11():574263. PubMed ID: 33117288 [TBL] [Abstract][Full Text] [Related]
12. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients]. Wang SY; Wang S Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428 [TBL] [Abstract][Full Text] [Related]
13. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161 [TBL] [Abstract][Full Text] [Related]
14. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments. Silva C; Ribeiro Rama AC; Reis Soares S; Moura-Ramos M; Almeida-Santos T J Ovarian Res; 2019 Oct; 12(1):102. PubMed ID: 31672154 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study. Ünal Ç; Ordu Ç; Özmen T; İlgun AS; Çelebi F; Baysal B; Özkurt E; Duymaz T; Erdoğan İyigün Z; Kurt S; Öztürk MA; Pilancı KN; Alço G; Yararbaş K; Kayan Tapan T; Güven DC; Soybir G; Özmen V Curr Oncol; 2023 Oct; 30(10):9217-9229. PubMed ID: 37887566 [TBL] [Abstract][Full Text] [Related]
16. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Birch Petersen K; Hvidman HW; Forman JL; Pinborg A; Larsen EC; Macklon KT; Sylvest R; Andersen AN Hum Reprod; 2015 Oct; 30(10):2364-75. PubMed ID: 26311148 [TBL] [Abstract][Full Text] [Related]
17. Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. A follow-up study. Al-Rawi SA; Saleh BO; Al-Naqqash MA Saudi Med J; 2018 Jul; 39(7):733-735. PubMed ID: 29968900 [TBL] [Abstract][Full Text] [Related]
18. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601 [TBL] [Abstract][Full Text] [Related]
19. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113 [TBL] [Abstract][Full Text] [Related]
20. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Anderson RA; Themmen AP; Al-Qahtani A; Groome NP; Cameron DA Hum Reprod; 2006 Oct; 21(10):2583-92. PubMed ID: 16820385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]